Drug Interactions Corner

Back to articles

New Diagnostic Test Approved for CYP 2D6 and 2C19 Genotyping

KEY POINT

Accurate patient-specific determination of the functional status of cytochrome (CYP) P450 enzymes can help clinicians predict and manage potential drug metabolism–related problems. A new FDA-approved test from Roche Diagnostics, the AmpliChip CYP450 Test, is able to provide just such information for CYP 2D6 and 2C19 enzymes.

SOURCES

Roche Diagnostics news release. January 12, 2005.

Lexi-Comp’s Pharmacogenomics Handbook. Humma LM, Ellingrod VL, Kolesar JM, eds. Hudson, Ohio: Lexi-Comp, Inc.; 2003.

Lexi-Comp’s Drug Interactions Handbook. Bachmann KA, Lewis JD, Fuller MA, Bonfiglio MF, eds. Hudson, Ohio: Lexi-Comp, Inc.; 2004.